Hemogenyx Pharmaceuticals Share Discussion Threads

[purple11] 19/12/2019 15:10

well atleast ppl are stopped from selling anymore then.

[jovi1] 19/12/2019 14:16

hope not but this is going down more on the short term as i cannot sell more that £100 in share at the moment no demand at all
hopefully better day ahead and clearly this type of company are only one good news away to make or brake

[purple11] 19/12/2019 10:37

shame theres no scappy buying to offset it!

[purple11] 19/12/2019 10:35

6.5m cap now.

id have thought 5m cap must be around the bottom if it gets there.then its up to HEMO.

is it just AIM dross or have they got something?

[johntopdog] 16/12/2019 23:00

Purple...I would have thought you would have known his name is Beeston not Beaston if you have been receiving such emails

[purple11] 13/12/2019 10:21

weve been emailing eachother since silf days. he doesn't work at hemo anymore so can say what he likes.im hoping he may have his ear to the ground still.hes certainly v confident.

[on target] 12/12/2019 16:21

Beeston is unlikely to email a total stranger with inside information, so I would guess - if you did receive an email - that he knows no more than the rest of us?

[dave4545] 12/12/2019 16:16

Maybe but do not log out as purple11 and then log back in as runawaypaul to try and deceive people eh !

[purple11] 12/12/2019 15:07

if the email proves correct they'll be multiple posts by multiple users flooding the bbs for days.don't shoot the messenger -this will rocket!

[dave4545] 12/12/2019 14:58

I thought you had gave up that lark of using multiple names paul ?

[runwaypaul] 12/12/2019 14:44

could be a perfect entry here if Beaston knows something we don't.

[purple11] 12/12/2019 14:35

he's not working for hemo anymore so can say what he likes I guess.maybe he still has an inside tac on what is going on.hope hes right.gl

[purple11] 12/12/2019 14:24

6p when news lands?

[purple11] 11/12/2019 15:31

just had an email from a beaston saying hes expecting the global pharma deal to land v shortly and to hang in there.hope hes right.he says he still hasn't sold a single share and is expecting big gains ahead.

[tsmith2] 25/11/2019 22:55

Agree the share price is just plain silly Should be a multiple

[johntopdog] 25/11/2019 22:52

An excellent presentation and most of it beyond me...but it all sounds very exciting and very promising and things are progressing well..share price ridiculous

[purple11] 25/11/2019 19:34

Presentation at Investival

[badger60] 25/11/2019 03:50

Good to see a bit of volume and share price increase, and hopefully it will continue this week. I think that there are not many willing sellers/freefloat at these levels, which should further enhance the share price

[purple11] 19/11/2019 15:46

sadly the whole market is completely dead atm.there is no real volume anywhere.

[on target] 18/11/2019 10:33

Investival showcase tomorrow do you mean?

[tsmith2] 18/11/2019 10:16

Should focus minds at oncology conference

[purple11] 18/11/2019 09:47

second phase global pharma deal


GlobalCo development agreement

Work with a global international pharmaceutical company ("GlobalCo") on the Company's CDX antibody ("CDX") as a clinical candidate, first announced on 14 May 2018, has entered its second phase. The Company and GlobalCo continue to develop CDX towards clinical readiness and have initiated manufacturability assessment and follow-up tests of the antibody.

Hemogenyx and GlobalCo remain optimistic as to the outcome of these tests based on results to date and look forward to providing further updates as the development work progresses.

[purple11] 18/11/2019 09:46

Good solid progress

Operational Update

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments of blood diseases, is pleased to announce the following update on its activities.

CDX Antibodies

GlobalCo development agreement

Work with a global international pharmaceutical company ("GlobalCo") on the Company's CDX antibody ("CDX") as a clinical candidate, first announced on 14 May 2018, has entered its second phase. The Company and GlobalCo continue to develop CDX towards clinical readiness and have initiated manufacturability assessment and follow-up tests of the antibody.

Hemogenyx and GlobalCo remain optimistic as to the outcome of these tests based on results to date and look forward to providing further updates as the development work progresses.

Expansion of CDX into additional indications

In parallel to the work performed with GlobalCo, the Company is also progressing research into the use of CDX as a treatment for subsets of Acute Myeloid Leukemia ("AML"), Acute Lymphoblastic Leukemia ("ALL") and Myelodysplastic Syndrome ("MDS"). The antibody has been shown to be effective in vivo against AML-derived cells using the Company's proprietary humanised mice. These potential applications of the CDX product candidate could provide life-saving treatments against three forms of blood cancer which remain resistant to current modes of treatment.

The use of CDX as a therapy against blood malignancies is beyond what was anticipated when the Company listed in 2017. At this time CDX was being developed purely as a conditioning product for bone marrow transplantation.

Intellectual property

As announced on 12 July 2019, the Company filed a new patent application for CDX in relation to conditioning patients for bone marrow transplantation and treatments for blood cancers such as AML and ALL. An additional composition of matter patent application is expected to be filed upon the completion of the development agreement with the GlobalCo.

Humanised Mice

As announced on 23 October 2019, Immugenyx, LLC ("Immugenyx"), the Company's wholly-owned subsidiary, entered into a research agreement with the above-mentioned GlobalCo to develop Immugenyx's advanced humanised mice as a tool for drug development and testing. If the first phase of research produces successful results, Hemogenyx anticipates that further phases of the research will be commissioned, as has been the case with other trials using the Company's humanised mice.

Immugenyx has already completed or entered into humanised mouse related projects with a number of other large pharmaceutical companies, including the previously announced agreement with Janssen Research & Development, LLC ("Janssen"), to build a model of human systemic lupus erythematosus, an autoimmune disease. These agreements confirm the value of the new type of humanised mice within the pharmaceutical community and give the Company an immediate revenue stream which the Directors believe can be developed and promoted considerably more widely. Immugenyx is also in discussions with other pharmaceutical organisations for research agreements using its humanised mice.

Hu-PHEC Stem Cell Therapy

Hemogenyx-Cell SPRL is the Company's wholly-owned subsidiary, established to develop Hu-PHEC, the Company's stem cell therapy product, for the direct treatment of leukaemia and other blood diseases. This subsidiary has received an in principle offer of grant/loan funding from the South Belgian regional authorities. The Directors are currently reviewing the terms of this offer and the conditions attached.

Patents in relation to the Hu-PHEC development are also at an advanced stage in the pipeline.

The Directors are therefore pleased to announce positive progress in relation to all three of the Company's areas of activity